[go: up one dir, main page]

CO7151528A2 - Anticuerpos de anti-transglutaminasa 2 - Google Patents

Anticuerpos de anti-transglutaminasa 2

Info

Publication number
CO7151528A2
CO7151528A2 CO14281628A CO14281628A CO7151528A2 CO 7151528 A2 CO7151528 A2 CO 7151528A2 CO 14281628 A CO14281628 A CO 14281628A CO 14281628 A CO14281628 A CO 14281628A CO 7151528 A2 CO7151528 A2 CO 7151528A2
Authority
CO
Colombia
Prior art keywords
transglutaminase
antibodies
provides antibodies
core
scarring
Prior art date
Application number
CO14281628A
Other languages
English (en)
Inventor
Tim Johnson
Phil Watson
David Matthews
Alex Brown
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of CO7151528A2 publication Critical patent/CO7151528A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)

Abstract

La invención proporciona anticuerpos y fragmentos de unión a antigeno de los mismos que se unen de forma selectiva a un epitopo dentro de la región de núcleo de la transglutaminasa del tipo 2 (TG2). Se proporcionan epitopos novedosos dentro del núcleo de TG2. La invención proporciona anticuerpos inhibidores de TG2 humana y usos de los mismos, particularmente en medicina, por ejemplo en el tratamiento y/o diagnóstico de afecciones que incluyen enfermedad Celiaca, cicatrización, enfermedades relacionadas con fibrosis, enfermedades neurodegenerativas/ neurolológicas y cáncer.
CO14281628A 2012-05-24 2014-12-23 Anticuerpos de anti-transglutaminasa 2 CO7151528A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds

Publications (1)

Publication Number Publication Date
CO7151528A2 true CO7151528A2 (es) 2014-12-29

Family

ID=46546551

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14281628A CO7151528A2 (es) 2012-05-24 2014-12-23 Anticuerpos de anti-transglutaminasa 2

Country Status (40)

Country Link
US (3) US10005846B2 (es)
EP (2) EP3521315B1 (es)
JP (2) JP6411998B2 (es)
KR (1) KR102091223B1 (es)
CN (1) CN104321346B (es)
AU (1) AU2013265025B2 (es)
BR (1) BR112014029089B1 (es)
CA (1) CA2874488C (es)
CL (1) CL2014003125A1 (es)
CO (1) CO7151528A2 (es)
CY (2) CY1121932T1 (es)
DK (2) DK3521315T3 (es)
EA (1) EA036810B1 (es)
EC (1) ECSP14030942A (es)
ES (2) ES2835383T3 (es)
GB (1) GB201209096D0 (es)
HK (1) HK1203974A1 (es)
HR (2) HRP20191293T1 (es)
HU (2) HUE052490T2 (es)
IL (1) IL235369B (es)
IN (1) IN2014MN02231A (es)
LT (2) LT2855530T (es)
MA (1) MA37670B1 (es)
ME (1) ME03393B (es)
MX (1) MX367517B (es)
MY (1) MY185966A (es)
NZ (1) NZ701424A (es)
PE (1) PE20150346A1 (es)
PH (1) PH12014502582A1 (es)
PL (2) PL2855530T3 (es)
PT (2) PT3521315T (es)
RS (2) RS61286B1 (es)
SG (1) SG11201407053YA (es)
SI (2) SI2855530T1 (es)
SM (2) SMT201900407T1 (es)
TN (1) TN2014000458A1 (es)
TR (1) TR201906781T4 (es)
UA (1) UA117657C2 (es)
WO (1) WO2013175229A1 (es)
ZA (1) ZA201408213B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
AU2022393224A1 (en) 2021-11-18 2024-06-27 UCB Biopharma SRL Method for the treatment of progressive chronic interstitial lung disease
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
AU1268192A (en) 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
AU6620596A (en) 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
WO2004069175A2 (en) 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2008063760A2 (en) 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
JP5736176B2 (ja) * 2008-04-24 2015-06-17 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびその使用
WO2010105302A1 (en) 2009-03-19 2010-09-23 Queensland University Of Technology Targets for growth factor signalling and methods of therapy
HU0900195D0 (en) 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
WO2011151395A2 (en) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Also Published As

Publication number Publication date
EP3521315B1 (en) 2020-10-14
HUE045539T2 (hu) 2019-12-30
HK1203974A1 (en) 2015-11-06
EA201492162A1 (ru) 2015-03-31
KR102091223B1 (ko) 2020-03-20
EP2855530A1 (en) 2015-04-08
NZ701424A (en) 2016-08-26
JP2018166510A (ja) 2018-11-01
HUE052490T2 (hu) 2021-04-28
MA37670A1 (fr) 2016-05-31
US10961319B2 (en) 2021-03-30
UA117657C2 (uk) 2018-09-10
SG11201407053YA (en) 2014-12-30
EA036810B1 (ru) 2020-12-23
PT3521315T (pt) 2020-10-29
CY1123926T1 (el) 2022-05-27
SI2855530T1 (sl) 2019-08-30
LT2855530T (lt) 2019-07-25
US20210101999A1 (en) 2021-04-08
ECSP14030942A (es) 2015-09-30
CY1121932T1 (el) 2020-10-14
US10005846B2 (en) 2018-06-26
GB201209096D0 (en) 2012-07-04
ME03393B (me) 2020-01-20
JP6411998B2 (ja) 2018-10-24
EP2855530B1 (en) 2019-05-01
PL3521315T3 (pl) 2021-08-23
CN104321346B (zh) 2018-12-07
CA2874488C (en) 2021-09-07
SMT202100014T1 (it) 2021-03-15
HRP20191293T1 (hr) 2019-10-18
ZA201408213B (en) 2020-02-26
IN2014MN02231A (es) 2015-07-24
IL235369B (en) 2019-05-30
MA37670B1 (fr) 2019-12-31
US20150218289A1 (en) 2015-08-06
LT3521315T (lt) 2020-12-28
DK3521315T3 (da) 2020-11-09
MX2014014264A (es) 2015-05-15
TN2014000458A1 (en) 2016-03-30
AU2013265025B2 (en) 2018-04-26
PH12014502582B1 (en) 2015-01-21
RS59135B1 (sr) 2019-09-30
EP3521315A1 (en) 2019-08-07
SI3521315T1 (sl) 2020-12-31
MX367517B (es) 2019-08-26
PL2855530T3 (pl) 2019-10-31
JP2015519897A (ja) 2015-07-16
WO2013175229A1 (en) 2013-11-28
CN104321346A (zh) 2015-01-28
DK2855530T3 (da) 2019-06-24
ES2835383T3 (es) 2021-06-22
BR112014029089B1 (pt) 2023-04-25
KR20150013340A (ko) 2015-02-04
BR112014029089A2 (pt) 2019-06-25
ES2728856T3 (es) 2019-10-29
HRP20202059T1 (hr) 2021-02-19
AU2013265025A1 (en) 2014-12-04
PE20150346A1 (es) 2015-03-05
TR201906781T4 (tr) 2019-05-21
SMT201900407T1 (it) 2019-09-09
CA2874488A1 (en) 2013-11-28
US11718686B2 (en) 2023-08-08
PH12014502582A1 (en) 2015-01-21
CL2014003125A1 (es) 2015-08-21
RS61286B1 (sr) 2021-02-26
IL235369A0 (en) 2014-12-31
MY185966A (en) 2021-06-14
US20180355060A1 (en) 2018-12-13
PT2855530T (pt) 2019-07-08

Similar Documents

Publication Publication Date Title
CO7151528A2 (es) Anticuerpos de anti-transglutaminasa 2
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CO2018000809A2 (es) Anticuerpos para cd40
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
MY197061A (en) Improved 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
NI201200144A (es) Anticuerpos humanizados de il - 25
ECSP14029713A (es) Moléculas de unión il-6
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CL2019000702A1 (es) Anticuerpos anti-gm-csf y usos de los mismos.
CR20190086A (es) Anticuerpo o un fragmento de union a antígeno del mismo, capaz de unirsea un receptor humano de interleucina-6
CR20140095A (es) Un conjugado citotóxico ca6 antigeno-específico y métodos para utilizar el mismo
TH153192A (th) แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี